Defined Polymeric Materials for Gene Delivery

Purpose: Polymeric gene delivery carriers such as PEI and poly(L-lysine) are heterogeneous and polydisperse, making site-specific multifunctional modification, structure–activity relationship studies, and reproducible clinical manufacturing difficult. This review argues that precisely defined polymeric materials — dendrimers, peptides, and sequence-defined oligoaminoamides — are needed to overcome these limitations.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that chemically precise, monodisperse, sequence-defined or dendritic cationic carriers can incorporate shielding, targeting, endosomal escape, and bioreversible stabilization functions in a controlled manner, enabling more reproducible and effective nonviral gene delivery.

Aims: Describe the biological barriers that DNA/polymer complexes must overcome for successful gene delivery. - Review defined polymeric vectors for pDNA delivery, including dendrimers, peptide carriers, and sequence-defined oligoaminoamides. - Highlight how precise chemistry enables site-specific multifunctional modification and structure–activity relationship studies. - Discuss remaining challenges and future directions for defined polymeric gene delivery materials.

Delivery system: Carrier classes: Dendrimers, peptide-based carriers, and sequence-defined oligoaminoamide carriers. - Dendrimers: PAMAM, poly(propylenimine) (PPI), poly(L-lysine) dendrimers. - Peptides: Oligolysines, histidine-rich peptides, fusogenic peptides (Tat, melittin, INF, KALA), cysteine-containing bioreducible peptides. - Sequence-defined oligomers: Solid-phase peptide synthesis (SPPS)-assembled oligoaminoamides using artificial building blocks such as Stp, Gtp, Gtt, Ptp. - Payload: Plasmid DNA (pDNA) primarily; also applicable to antisense oligonucleotides, siRNA, miRNA, and mRNA. - Functional modifications: PEG or pHPMA shielding; targeting ligands (transferrin, folate, EGF, RGD, B6, lactose); bioreversible disulfide crosslinking; histidine/imidazole buffering; lipid/fatty acid membrane-lytic domains; nuclear localization signals. - Polyplex type: Electrostatic pDNA/polymer nanoparticles (“polyplexes”).

Approach: Review of preclinical and clinical literature. Reviewed studies include in vitro cell lines such as HeLa, HEK, HepG2, A431, and others; in vivo tumor-bearing mouse models and brain-targeted delivery; and a human clinical study using PEG-modified Lys30 for CFTR gene delivery to cystic fibrosis airway epithelium. No new primary experiments are reported.

Key methods: Polyplex formation and stability (gel electrophoresis, N/P ratios). - Transfection efficiency (reporter gene expression). - Cytotoxicity/cell viability. - Buffering capacity and endosomal escape. - Cellular uptake and intracellular trafficking. - In vivo gene expression and tumor accumulation. - Structure–activity relationship analysis by comparing defined oligomer sequences, topologies, and building blocks.

Key results: PAMAM dendrimers: Generation 6 (DG6) was an optimal compromise between efficiency and toxicity; partial amide hydrolysis increased transfection activity approximately 100-fold. - Fluorinated PAMAM G5: Low toxicity and improved transfection at extremely low N/P ratios, comparable or superior to Lipofectamine 2000 and SuperFect. - Fluorinated PPI dendrimers: Formed pDNA polyplexes at very low N/P ratios (<2), showed low toxicity, and strongly enhanced transfection in HeLa and HEK cells, comparable or superior to SuperFect. - Sequence-defined oligomers: Optimal length was 20–30 Stp units; these showed approximately 6-fold higher transfection efficiency and 10-fold lower cytotoxicity than linear PEI (22 kDa). - Histidine incorporation: Increased endosomal buffer capacity and further improved gene transfer in vitro and in vivo in a tumor mouse model. - Lipid-containing oligomers: Oleic acid and linoleic acid modifications mediated endosomal pH-specific lytic activity and high transfection efficiency. - Targeted oligomers: Histidine-containing, receptor-targeted oligomers achieved high transfection without chloroquine. - Clinical example: A defined Lys30 terminally modified with PEG was used in human clinical studies for CFTR gene expression in cystic fibrosis airway epithelium.

Interpretation: Precise, defined polymeric materials are expected to play an important role in future nonviral gene delivery. Structural precision enables site-specific multifunctional modification, reproducible manufacturing, and better structure–activity relationship studies. Multifunctional, bioresponsive polyplexes are needed to overcome delivery barriers. Current drawbacks include complexity in reproducibly forming supramolecular polyplexes and relatively low gene transfer efficiency, especially in nondividing cells. Further refinement should improve medical and pharmaceutical impact.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Many discussed systems remain preclinical; clinical data are limited. - Polymer heterogeneity and polydispersity remain major technical obstacles. - Reproducible supramolecular polyplex assembly is still challenging. - Gene transfer efficiency remains relatively low, especially in nondividing cells. - Long-term safety, large-animal validation, and detailed pharmacokinetics/biodistribution are not comprehensively addressed.